June 20, 2025

Gut Bacteria Predict Chemotherapy-Related Heart Damage

Specific gut bacteria correlate with biomarkers indicating increased risk of cardiotoxicity in breast cancer patients before chemotherapy treatment.

Conexiant

June 19, 2025

Heavy Drinking Consistently Linked To Heart Risks

New research finds that heavy alcohol consumption consistently raises cardiovascular risks, while evidence for protective effects of light drinking remains inconclusive.

Conexiant

June 19, 2025

Plaque Calcification May Predict Future Hemorrhage Risk

New research tracked subclinical carotid plaque changes over six years and found that plaques with calcification were twice as likely to develop intraplaque hemorrhage, with men showing greater risk for complex plaque progression.

Conexiant

June 19, 2025

Is More Fiber the Heart’s Ally?

A long-term U.S. study found that greater adherence to a plant-based cholesterol-lowering diet was linked to lower cardiovascular, coronary heart disease, and all-cause mortality.

Conexiant

June 17, 2025

Is Stroke Risk Lower with Semaglutide?

Semaglutide lowered stroke risk compared to empagliflozin in adults with type 2 diabetes, though overall mortality and heart attack rates were similar between the two drugs.

Conexiant

June 13, 2025

RSV Vaccine Approved for Younger Adults

The FDA has approved Moderna’s mRESVIA vaccine for adults aged 18 to 59 who are at increased risk for RSV, expanding its indication beyond older adults.

Conexiant

June 13, 2025

Obicetrapib May Offer LDL Benefit

In a randomized trial of more than 2,500 patients at high cardiovascular risk, obicetrapib significantly reduced low-density lipoprotein cholesterol levels when added to existing lipid-lowering therapy.

Conexiant

June 13, 2025

5-Year Mortality Increases After Ocular Trauma in Geriatric Patients

Comorbidities, such as dementia, cardiovascular issues, and diabetes, also pointed to higher mortality in ocular trauma cases.

Optometric Management

June 13, 2025

Obicetrapib-Ezetimibe Combo Cuts LDL Nearly 50%

A phase 3 trial of an oral fixed-dose combination of obicetrapib and ezetimibe showed a nearly 50% reduction in LDL cholesterol levels in patients at high risk for heart disease, without added safety concerns.

Conexiant